Welcome to our dedicated page for Moolec Science SEC filings (Ticker: MLEC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Moolec Science SA (NASDAQ: MLEC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. Moolec files reports such as Form 20-F annual reports and Form 6-K current reports under the Securities Exchange Act of 1934, detailing material events, corporate actions, and listing-related matters for investors and analysts.
Recent Form 6-K filings referenced in public information include disclosures about Nasdaq determination letters regarding minimum bid price requirements, stockholders’ equity thresholds, and delays in filing the Form 20-F. Moolec has also used Form 6-K to report on its extraordinary general meeting of shareholders, including approval of share consolidations, and to describe appeals and hearings with Nasdaq’s Listing Qualifications Department and Hearings Panel.
Filings related to share structure changes, such as reverse stock splits and subsequent share consolidations, outline how Moolec reduced the number of issued and outstanding ordinary shares and adjusted par value per share, while stating that these actions do not affect the company’s business or operations. Other filings incorporate press releases by reference, including those announcing the closing of a strategic business combination with Bioceres Group Limited, Gentle Technologies Corp, and Nutrecon LLC.
On Stock Titan, users can review Moolec’s SEC filings alongside AI-powered summaries that explain the key points of lengthy documents. This includes highlighting the implications of listing compliance notices, share consolidations, and other corporate actions disclosed on Form 6-K, as well as providing context for how these events relate to Moolec’s broader strategy in food-tech, life sciences, and agricultural biotechnology.
Agriculture Investment Group Corp. became the controlling shareholder of Moolec Science SA by converting preference shares into ordinary shares. It now beneficially owns 1,354,186 ordinary shares, representing 65.1% of Moolec’s outstanding ordinary shares. Total ordinary shares outstanding were 2,080,304 as of January 5, 2026.
The conversion followed a $5,473,425 aggregate amount of preference shares being exchanged for ordinary shares under a Subscription Agreement originally dated December 9, 2024 and later amended. Agriculture Investment Group now has sole voting and dispositive power over its entire Moolec stake.
Agriculture Investment Group Corp. became the controlling shareholder of Moolec Science SA, reporting beneficial ownership of 1,354,186 ordinary shares, or 65.1% of the company, after converting preference shares into ordinary shares under a prior subscription agreement.
The ownership percentage is based on 2,080,304 ordinary shares outstanding as of January 5, 2026. Agriculture Investment Group Corp. holds sole voting and dispositive power over its shares and states it may review and change its intentions toward Moolec Science over time.
Moolec Science reports a change in control after Agriculture Investment Group Corp. (AIGC) became its controlling shareholder. On April 1, 2026, AIGC held 65.1% of Moolec’s outstanding shares following a partial conversion of its preference shares into ordinary shares under an existing subscription agreement. As a foreign private issuer, Moolec has chosen to follow home country practice instead of Nasdaq’s usual requirement for prior shareholder approval in transactions that result in a change of control.
Moolec Science SA Chief Financial Officer Valeria Ines Falottico filed an initial insider ownership report listing her holdings in the company’s ordinary shares and equity awards. She directly holds 891 ordinary shares.
The filing also lists share options over 2,222 ordinary shares at an exercise price of $7.14 per share, with expiration dates in 2031, 2032, and 2033. In addition, she holds restricted share unit awards linked to 2,333 underlying ordinary shares at $14.28 per share and 2,333 underlying ordinary shares at $28.56 per share, both expiring in 2031.
Moolec Science SA director Lorenzo Varela has filed a Form 3 reporting his initial beneficial ownership in the company. The filing shows three direct option-based positions over ordinary shares, each with a $7.14 exercise price and expirations in 2031, 2032, and 2033.
The underlying options cover 934, 933, and 933 ordinary shares, respectively, and are structured as share options rather than open-market share purchases or sales. The disclosure is administrative, establishing his baseline holdings without reporting any new buy or sell transactions.
Moolec Science SA Chief Technology Officer Paola Alexandra Diaz Dellavalle filed an initial ownership report showing direct holdings of share options over ordinary shares. The filing lists options to acquire 934, 933 and 933 ordinary shares at an exercise price of $7.14 per share, with expiration dates in 2031, 2032 and 2033.
Moolec Science SA filed an initial insider holdings report for Chief Technology Officer Paola Alexandra Diaz Dellavalle. She holds share options over 934 ordinary shares at an exercise price of 7.1400 per share expiring on June 30, 2031, and additional options over 933 shares each expiring on June 30, 2032 and June 30, 2033. These entries reflect her option-based equity position rather than new share purchases or sales.
Moolec Science SA director Abelleyra Llodra Diego Juan has filed a Form 3 reporting direct holdings of share options over ordinary shares. The filing lists three option grants covering 934, 933 and 933 underlying ordinary shares at an exercise price of 7.1400, expiring on 2031-06-30, 2032-06-30 and 2033-06-30. These entries describe existing derivative positions rather than new open‑market purchases or sales.
Moolec Science SA filed an initial ownership report for Chief Executive Officer Alejandro Carlos Antalich, detailing his equity-based awards in ordinary shares. The filing lists share options for 3,334, 3,333 and 3,333 underlying shares at an exercise price of $7.1400, expiring between 2031 and 2033.
It also shows restricted share units linked to 6,667 and 6,666 underlying ordinary shares at exercise prices of $14.2800 and $28.5600, expiring on February 6, 2031. These entries describe existing awards and do not reflect new open-market purchases or sales.
Moolec Science SA director Leon Bentancor Oscar Alejandro filed an initial Form 3 reporting option-based holdings in the company’s ordinary shares. He holds three direct share option positions, each with an exercise price of 7.1400 per share, covering 934, 933 and 933 ordinary shares with expirations in 2031, 2032 and 2033.